Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin

Romidepsin is a histone deacetylase inhibitor approved by the FDA for the treatment of patients with cutaneous or peripheral T-cell lymphoma who have received prior systemic therapy. The objective of this analysis was to evaluate the potential QTc effects of romidepsin. Patients with advanced malign...

Descripción completa

Detalles Bibliográficos
Autores principales: Sager, Philip T, Balser, Barbara, Wolfson, Julie, Nichols, Jean, Pilot, Richard, Jones, Suzanne, Burris, Howard A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559029/
https://www.ncbi.nlm.nih.gov/pubmed/25914207
http://dx.doi.org/10.1002/cam4.467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559029/
https://www.ncbi.nlm.nih.gov/pubmed/25914207
http://dx.doi.org/10.1002/cam4.467

Ejemplares similares